greeksoup/ stock research
Stock research / United States / REGN · Pharmaceutical Preparations · Nasdaq

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron is a fully integrated biotechnology company that invents, develops, manufactures and commercialises medicines for people with serious diseases. Its products and candidates address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. Its stated strategy is to keep a foundation in scientific research and drug development on its own proprietary technologies and build clinical development, manufacturing and commercial capability on top of it.

Regeneron Pharmaceuticals, Inc.

Regeneron is a fully integrated biotechnology company that invents, develops, manufactures and commercialises medicines for people with serious diseases. Its products and candidates address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. Its stated strategy is to keep a foundation in scientific research and drug development on its own proprietary technologies and build clinical development, manufacturing and commercial capability on top of it.

At the end of 2025 it had 15,410 full-time employees: 11,961 in the United States, 2,149 in Ireland and 1,300 elsewhere, mainly the United Kingdom, Japan and Germany. Of those, 2,591 worked in research and preclinical development, 2,274 in global clinical development and regulatory affairs, and 6,717 in industrial operations and product supply. More than 1,800 of the full-time employees hold a PhD or an MD.

The eye business

EYLEA, aflibercept, is approved in the United States, the European Union and Japan across wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion, and additionally in diabetic retinopathy, myopic choroidal neovascularisation, neovascular glaucoma and retinopathy of prematurity depending on the territory. EYLEA HD is the 8 mg version, approved in the same three territories for wet age-related macular degeneration and diabetic macular edema, and in the United States for diabetic retinopathy. Regeneron records product sales of both in the United States, while Bayer records sales outside it and Regeneron takes its share of those profits through collaboration revenue.

Dupixent and Kevzara, with Sanofi

Dupixent, dupilumab, covers atopic dermatitis in patients from six months old, asthma in adults, adolescents and children aged six to eleven, chronic rhinosinusitis with nasal polyposis, chronic obstructive pulmonary disease and eosinophilic esophagitis, among other indications, across the three main territories. Kevzara, sarilumab, covers rheumatoid arthritis, polymyalgia rheumatica and polyarticular juvenile idiopathic arthritis. Sanofi records global product sales of both, and Regeneron records its share of the profits as collaboration revenue.

Oncology and haematology

Libtayo, cemiplimab, covers first-line metastatic or locally advanced non-small cell lung cancer as a single agent and with chemotherapy, basal cell carcinoma, cutaneous squamous cell carcinoma including in the adjuvant setting, and second-line cervical cancer. Ordspono, odronextamab, is approved in the European Union for follicular lymphoma and diffuse large B-cell lymphoma. Lynozyfic, linvoseltamab, is approved for relapsed or refractory multiple myeloma.

The rest of the portfolio

Praluent, alirocumab, reduces cardiovascular risk and treats hypercholesterolemia, including heterozygous familial hypercholesterolemia in patients from the age of eight and homozygous familial hypercholesterolemia. Evkeeza, evinacumab, treats homozygous familial hypercholesterolemia in adults, adolescents and children. Veopoz, pozelimab, and ARCALYST, rilonacept, cover rare conditions, ZALTRAP is an intravenous infusion, and Inmazeb is a three-antibody combination for infection caused by Zaire ebolavirus.

The technologies underneath

Two technologies make the protein therapeutics. The first fuses receptor components to the constant region of an antibody molecule to make a class of drugs the company calls Traps; EYLEA HD, EYLEA, ZALTRAP and ARCALYST were all generated that way. The second is VelociSuite, used to discover, develop and produce fully human antibodies against both secreted and cell-surface targets, and also to produce bispecific antibodies, antibody-protein fusions and antibody conjugates. Inside it, the VelocImmune mouse platform produces fully human antibodies; it was made by replacing six megabases of mouse immunoglobulin gene loci with the corresponding human loci. VelociMab screens antibodies and generates expression cell lines quickly, and Veloci-Bi generates full-length bispecific antibodies similar to native ones, which can be made with standard antibody manufacturing. Genetic medicine platforms sit alongside these as complementary approaches.

The Regeneron Genetics Center, a wholly owned subsidiary, works on the other end of the problem. It uses de-identified clinical, genomic, proteomic and other molecular data from consenting volunteers around the world to find medically relevant associations in a blinded fashion, with the aim of using human genetics to discover and validate the genetic factors that cause or influence diseases with major unmet need.

From Regeneron's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Regeneron Pharmaceuticals became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 30 October 2026
Revenue
$5.1 billion
+36.3% on the year · +19.2% on the quarter
Q4 FY2024Q3 FY2026
Net income
$1.9 billion
+33.5% on the year · +50.3% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$18.45
+35.5% on the year · +50.9% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 4 February 2026
Revenue
$14.3 billion
+1.0% on the year
FY2018FY2025
Net income
$4.5 billion
+2.1% on the year
FY2018FY2025
Diluted EPS
$41.48
+8.2% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsRegeneron Pharmaceuticals (REGN) reported revenue of $14.3 billion for fiscal 2025, the year ended 31 December 2025, up 1.0% on the year before. Net income was $4.5 billion and diluted earnings per share $41.48. Revenue was $14.2 billion in fiscal 2024, $13.1 billion in fiscal 2023, $12.2 billion in fiscal 2022 and $16.1 billion in fiscal 2021. Net income in the same years was $4.4 billion, $4.0 billion, $4.3 billion and $8.1 billion. Over the twelve months to 30 September 2026, Regeneron Pharmaceuticals reported revenue of $16.9 billion and net income of $4.8 billion. Revenue grew 11.0% a year, compounded, over the five years to fiscal 2025. Regeneron Pharmaceuticals declared $3.70 a share in dividends over the last four quarters. At 30 September 2026 it carried $2.0 billion of debt and $3.7 billion of cash. At the close of 6 November 2026 the market cap of Regeneron Pharmaceuticals was $95.5 billion, 20.0 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE14.4%
ROCE13.7%
Operating margin28.8%
Net margin28.5%
FCF margin22.6%
Interest cover104.2x
Debt to equity0.06x
Cash conversion1.01x
Share count, last 12 months-1.8%
Sales CAGR, 3 years5.6%
Profit CAGR, 3 years1.3%
EPS, TTM$45.29

At the close of 6 November 2026

Price$904.38
Market cap$95.5 billion
Stock P/E20.0x
Price to book2.9x
EV / EBITDA17.4x
Dividend yield0.4%
Market cap / sales5.7x
52-week high$973.80
52-week low$600.66
Price, 1 year39.8%
Price CAGR, 3 years2.9%
Price CAGR, 5 years8.1%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Regeneron Pharmaceuticals, Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
REGNgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue4,9522,9652,8572,9363,4143,1623,1583,3633,4343,1453,5473,7213,7893,0293,6763,7543,8843,6054,2915,116
R&D7868447949111,0431,1011,0851,0751,1771,2481,2001,2721,4121,3271,4221,4751,6261,5441,6321,795
SG&A560450476529660601652640738689759714792633634658775648662678
Operating income2,6401,2581,1101,2241,1479471,0161,1119737511,0701,1809905921,0801,0278806431,2942,048
Operating margin53%42%39%42%34%30%32%33%28%24%30%32%26%20%29%27%23%18%30%40%
Interest expense14.113.613.115.317.418.018.917.818.316.114.813.810.58.73.619.312.212.911.010.6
Pre-tax income2,5031,0619631,5101,3258581,0831,1111,1487011,6281,4939589051,5191,7631,0448311,5282,284
Tax rate11%8%12%13%10%5%11%9%-1%-3%12%10%4%11%8%17%19%13%15%15%
Net income2,2299748521,3161,1978189681,0081,1607221,4321,3419188091,3921,4608457271,2971,949
Net margin45%33%30%45%35%26%31%30%34%23%40%36%24%27%38%39%22%20%30%38%
Diluted EPS$19.58$8.61$7.47$11.66$10.50$7.17$8.50$8.89$10.19$6.27$12.41$11.54$8.06$7.27$12.81$13.62$7.86$6.75$12.23$18.45
Operating cash flow2,3722,1025646291,7201,3681,0221,1141,0901,5123541,2911,2631,0451,1441,6191,1711,0798131,783
Capital expenditure155142154142152178113176251134180242200229219201249231240300
Free cash flow2,2181,9604114861,5681,1899099388381,3791741,0491,0638169251,4179228485731,483
Buybacks8673583599354317116895462892916047359731,0411,0626646727941,169400
Dividends paidn/an/an/an/an/a0.00.00.00.00.00.00.00.093.892.691.292.797.896.895.7
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015FY2016 †FY2017FY2018 †FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Revenue2383794594461,3782,1052,8204,1044,8605,8725,1466,5588,49716,07212,17313,11714,20214,34316,896
Cost of revenue0.91.72.14.283.9118129242195203238403n/an/an/an/an/an/an/a
Gross profit2383784574421,2951,9872,6913,8624,6665,6704,9086,155n/an/an/an/an/an/an/a
Gross margin99.6%99.6%99.5%99.1%93.9%94.4%95.4%94.1%96.0%96.6%95.4%93.9%n/an/an/an/an/an/an/a
Research and development2753994895306268601,2711,6212,0522,0751,4692,4502,6472,8603,5924,4395,1325,8506,596
Selling, general and administrative48.952.965.21172113465198391,1781,3201,1271,3421,3461,8252,1162,6312,9542,7002,763
Operating income-86.2-74.1-97.5-2054587438241,2521,3312,0802,5342,2103,5778,9474,7394,0473,9913,5784,864
Operating margin-36.2%-19.5%-21.2%-46.0%33.2%35.3%29.2%30.5%27.4%35.4%49.3%33.7%42.1%55.7%38.9%30.9%28.1%24.9%28.8%
Interest expense7.82.39.121.345.346.437.414.27.225.128.230.256.957.359.473.055.243.846.7
Pre-tax income-76.8-72.0-104-2234146967611,2251,3302,0792,5542,4293,8109,3264,8594,1994,7805,2315,687
Income tax2.4-4.10.0-1.1-3362834235894348801093132971,250520246367726869
Effective tax raten/an/an/an/a-81.0%40.6%55.6%48.1%32.7%42.3%4.3%12.9%7.8%13.4%10.7%5.9%7.7%13.9%15.3%
Net income-79.1-67.8-104-2227504143386368961,1992,4442,1163,5138,0754,3383,9544,4134,5054,817
Net margin-33.2%-17.9%-22.8%-49.7%54.4%19.7%12.0%15.5%18.4%20.4%47.5%32.3%41.3%50.2%35.6%30.1%31.1%31.4%28.5%
Diluted EPSn/a-$0.85-$1.26-$2.45$6.75$3.72$2.98$5.52$7.70$10.34$21.29$18.46$30.52$71.97$38.22$34.77$38.34$41.48$45.29
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by product or service FY2020 to FY2025

FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Collaboration revenue1,1861,7712,0585,5036,0587,33151.1%
Net product sales5,56812,1176,8947,0787,6296,30944.0%
Other revenue5572813655365157034.9%
Sanofi collaboration revenue1,1861,9022,856n/an/an/an/a
Collaboration revenueNet product salesOther revenueSanofi collaboration revenue FY2020 to FY2022
8.5FY202016.1FY202112.2FY202213.1FY202314.2FY202414.3FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015FY2016 †FY2017FY2018 †FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Operating cash flow-89.1-69.999.2-142-74.65897521,3311,4861,3072,1952,4302,6187,0815,0154,5944,4204,9794,846
Capital expenditure34.997.399.757.249.31563336785122733834306155525907197568981,020
Free cash flow-124-167-0.5-199-1244324196539741,0341,8122,0002,0046,5294,4253,8753,6654,0803,826
Free cash flow margin-52.0%-44.1%-0.1%-44.6%-9.0%20.5%14.9%15.9%20.0%17.6%35.2%30.5%23.6%40.6%36.3%29.5%25.8%28.4%22.6%
Cash from investing30.8-2.1-437128-81.1-355-421-908-1,047-1,005-1,463-2,028-70.6-5,385-3,785-3,185-2,468-629-589
Cash from financing-19331.4243384-97.672.2-219-263-700-24.4-77.1-252-1,970-1,006-1,009-1,790-2,200-3,715-3,097
Depreciation and amortisation11.314.219.731.136.941.252.774.9105145148210236286341421483544513
Share-based compensation32.531.339.956.194.22153224595605074274644326027258859839941,006
Buybacksn/an/an/an/an/an/an/an/a0.00.04.42765,8471,6452,0832,2352,6033,4393,035
Dividends paidn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a0.00.0370383
Dividend per sharen/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a$3.70
Diluted shares, weightedn/an/a83m91m115m111m113m115m116m116m115m115m115m112m114m114m115m109m106m
Shares outstanding at period endn/a79m87m91mn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015FY2016 †FY2017FY2018 †FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity4223975284861,2571,9652,5503,6554,4496,1448,75711,09011,02518,76922,66425,97329,35431,25733,498
Short-term borrowingsn/an/an/an/an/an/an/an/an/an/an/a0.0n/an/an/an/an/an/an/a
Debtn/an/a0.02752973201470.00.00.00.00.01,9781,9801,9811,9831,9841,9861,987
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/an/an/a55.868.7204229n/a
Finance lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/a7147170.07207207207200.0
Other liabilitiesn/a3445625635276661,1411,9542,5242,6202,9773,0023,4424,6863,7934,3365,4976,3678,920
Total liabilities and equityn/a7411,0891,3242,0802,9513,8385,6096,9738,76411,73414,80517,16325,43529,21433,08037,75940,55944,405
Owned
Fixed assetsn/a2603473683805279741,5942,0832,3592,5762,8903,2223,482n/an/an/an/an/a
Intangible assetsn/an/an/an/an/an/an/an/an/an/an/an/an/a6.79161,0391,1491,2571,316
Investmentsn/a1815073193495487128681,3682,0833,0974,8534,5299,64711,22813,51115,42415,74815,199
Cash and equivalents2482071134842305366498095358131,4681,6182,1942,8863,1062,7302,4883,1183,659
Receivablesn/a2.92.328.35937877391,1521,3431,5391,7242,1004,1156,0365,3295,6676,2125,7417,579
Inventoryn/an/an/a16.628.670.41292393997261,1511,4161,9171,9512,4022,5803,0873,2012,895
Other assetsn/a90.31201084994836349471,2441,2451,7191,9281,1881,4256,2347,5529,39911,49413,758
Total assetsn/a7411,0891,3242,0802,9513,8385,6096,9738,76411,73414,80517,16325,43529,21433,08037,75940,55944,405
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded13.3%11.0%5.6%18.6%
Profit growth, compounded21.6%5.1%1.3%5.2%
Return on equity, average22.5%21.4%14.9%14.4%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Regeneron Pharmaceuticals' revenue in fiscal 2025?

Regeneron Pharmaceuticals (REGN) reported revenue of $14.3 billion for fiscal 2025, the year ended 31 December 2025, up 1.0% on the year before.

How much did Regeneron Pharmaceuticals earn in fiscal 2025?

Net income was $4.5 billion for fiscal 2025, and diluted earnings per share $41.48.

What is Regeneron Pharmaceuticals' P/E ratio?

At the close of 6 November 2026, Regeneron Pharmaceuticals traded at 20.0 times its earnings over the twelve months to 30 September 2026.

What is Regeneron Pharmaceuticals' market cap?

The market cap of Regeneron Pharmaceuticals was $95.5 billion at the close of 6 November 2026.

Does Regeneron Pharmaceuticals pay a dividend?

Yes. Regeneron Pharmaceuticals declared $3.70 a share in dividends over the four quarters to 30 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on REGN

Dividends$3.70 a share over the four quarters to 30 September 2026, a 0.41% yield
Filings17 in twelve months: 10 current reports (8-K), about 8 results of operations; 1 material agreement; 1 other events; 1 officer or director change; 1 shareholder vote
Planned insider sales21 Form 144 notices in twelve months, $58.1 million; latest 4 November 2026
Options tapeput/call 0.91 by open interest at the 6 November 2026 close; the straddle prices a 4.2% move to 13 November 2026
13F holders1,344 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading135 sales and 0 purchases on Form 4 in twelve months
Congress1 House trade disclosed in six months
Short interest2.1 million shares short, 3.18 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202630 October 2026EDGAR
10-Q30 June 202630 July 2026EDGAR
10-Q31 March 202629 April 2026EDGAR
10-K31 December 20254 February 2026EDGAR
10-Q30 September 202528 October 2025EDGAR
10-Q30 June 20251 August 2025EDGAR
10-Q31 March 202529 April 2025EDGAR
10-K31 December 20245 February 2025EDGAR
10-Q30 September 202431 October 2024EDGAR
10-Q30 June 20241 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.